Amgen, the makers of EPOGEN may find themselves in some tight competition that may help bring prices down and help keep costs down for clinics…if you didn’t know there’s an infringement trial going on, Amgen Vs Roche …Amgen alleges that Roche’s anemia treatment Mircera (also known as CERA) infringes on Amgen’s patents for Epogen and Aranesp.
FibroGen and Affymaxare two smaller biotech companies that have promising anemia treatments that do not infringe on existing patents and could compete in the anemia market in the coming years.
Would that be good news or bad news? Because of competition, do you think costs will go down?